Vertex Pharmaceuticals Incorporated (LON:0QZU)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 84.32B |
| Revenue (ttm) | 8.72B |
| Net Income (ttm) | 2.73B |
| Shares Out | n/a |
| EPS (ttm) | 10.58 |
| PE Ratio | 30.84 |
| Forward PE | 21.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,502 |
| Average Volume | 627 |
| Open | 446.57 |
| Previous Close | 445.32 |
| Day's Range | 443.91 - 455.99 |
| 52-Week Range | 362.50 - 519.68 |
| Beta | 0.32 |
| RSI | 58.07 |
| Earnings Date | Feb 2, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly in the Latin America e-commerce and fintec...
VRTX: Wells Fargo Raises Price Target to $515, Maintains Overweight Rating | VRTX Stock News
VRTX: Wells Fargo Raises Price Target to $515, Maintains Overweight Rating | VRTX Stock News
Vertex's Gene Therapy Works In Children With Blood Disorders
Vertex Pharmaceuticals presents clinical data demonstrating ... Full story available on Benzinga.com
Vertex Pharmaceuticals (VRTX) Reveals Promising CASGEVY Data for Young Patients
Vertex Pharmaceuticals (VRTX) Reveals Promising CASGEVY Data for Young Patients
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?
The stock has fallen from a peak back in April.
Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11
(RTTNews) - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced new data from pivotal studies of CASGEVY (exagamglogene autotemcel), demonstrating the transformative potential of the therapy ...
Vertex's gene therapy shows promise in younger children with blood disorders
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder...
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in peo...
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX)
$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 15 years by 6.85% on an annualized basis producing an average annual return of 18.9%. Currently, Vertex Pharmaceuticals...
Vertex Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Vertex Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock
The stock has climbed in the double-digits in recent years.
Check Out What Whales Are Doing With VRTX
Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ: VRTX). And retail traders should know. We noticed this today when the positions showed up on publ...
Vertex Pharmaceuticals (VRTX) Upgraded by Morgan Stanley with Optimistic Outlook
Vertex Pharmaceuticals (VRTX) Upgraded by Morgan Stanley with Optimistic Outlook
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsCharles Wagner -...
Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex Pharmaceuticals (VRTX) Receives Rating Upgrade from Morgan Stanley | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Receives Rating Upgrade from Morgan Stanley | VRTX Stock News
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Alphabet's advertising, cloud, and AI businesses are booming. Vertex is branching out beyond its still-successful core business.
3 Top Stocks to Buy in December
MercadoLibre has tremendous potential in the Latin American e-commerce and fintech markets. TransMedics Group is preparing to expand into Italy and has plenty of room to grow in the U.S. as well.
Vertex (VRTX) Q3 2025 Earnings Call Transcript
Vertex (VRTX) Q3 2025 Earnings Call Transcript
Where Will Vertex Pharmaceuticals Be in 5 Years
Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets beyon...
Vertex Pharmaceuticals (VRTX) Leads Hedge Fund Interest in Q3 2025
Vertex Pharmaceuticals (VRTX) Leads Hedge Fund Interest in Q3 2025
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon
Healthcare investments tend to be less cyclical than other stocks and help diversify your portfolio. Vertex has a profitable portfolio and promising pipeline, and its growth may be just getting starte...
Noteworthy ETF Outflows: IWF, VRTX, BX, MCK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected a...